Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3586-3590

  Riska, Paul F ^a,b   Kutlin, Andrei ^a   Ajiboye, Patrick ^a   Cua, Arnold ^a   Roblin, Patricia M ^a   Hammerschlag, Margaret R ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Box 56 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; MACROLIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHLAMYDOPHILA PNEUMONIAE; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLARITHROMYCIN; DNA PRIMERS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S;

EID: 4344591552     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3586-3590.2004     Document Type: Article

References (39)

1. Arthur, M., C. Molinas, and C. Mabilat. 1993. PCR detection of erm erythromycin resistance genes by using degenerate oligonucleotide primers, p. 534-538. In D. Persing, T. Smith, F. Tenover, and T. J. White (ed.), Diagnostic molecular microbiology: principles and applications. American Society for Microbiology, Washington, D.C.
2. Beatty, W. L., R. P. Morrison, and G. I. Byrne. 1994. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol. Rev. 58:686-699.
3. Block, S., J. Hedrick, M. R. Hammerschlag, G. H. Cassell, and J. C. Craft. 1995. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr. Infect. Dis. J. 14:471-477.
4. Boman, J., and M. R. Hammerschlag. 2002. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin. Microbiol. Rev. 15:1-20.
5. Canu, A., B. Malbruny, M. Coquemont, T. A. Davies, P. C. Appelbaum, and R. Leclercq. 2002. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:125-131.
6. Davies, T. A., G. A. Pankuch, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 1999. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:1177-1182.
7. Dessus-Babus, S., C. M. Bebear, A. Charron, C. Bebear, and B. de Barheyrac. 1998. Sequencing of gyrase and topoisomerase IV quinolone resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob. Agents Chemother. 42:2474-2481.
8. Dreses-Werringloer, U., I. Padubrin, B. Jurgens-Saathoff, A. P. Hudson, H. Zeidler, and L. Kohler. 2000. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. 44:3288-3297.
9. Dreses-Werringloer, U., I. Padubrin, H. Zeidler, and L. Kohler. 2001. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob. Agents Chemother. 45:3001-3008.
10. Gabay, M. P., and R. Jain. 2002. Role of antibiotics for the prevention of cardiovascular disease. Ann. Pharmacother. 36:1629-1636.
11. Galasso, G., and G. Manire. 1961. Effect of antiserum and antibiotics on persistent infection of HeLa cells with meningopneumonitis virus. J. Immunol. 86:382-385.
12. Gieffers, J., H. Fullgraf, J. Jahn, M. Klinger, K. Dalhoff, H. A. Katus, W. Solbach, and M. Maass. 2001. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103:351-356.
13. Hammerschlag, M. R. 2002. The intracellular life of chlamydiae. Semin. Pediatr. Infect. Dis. 13:239-248.
14. Hammerschlag, M. R., and P. M. Roblin. 2000. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int. J. Antimicrob. Agents 15:149-152.
15. Jones, R. B., P. B. Van der Pol, D. H. Martin, and M. K. Shepard. 1990. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J. Infect. Dis. 162:1309-1315.
16. Kaiman, S., W. Mitchell, R. Marathe, C. Lammel, J. Fan, R. W. Hyman, L. Olinger, J. Grimwood, R. W. Davis, and R. S. Stephens. 1999. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat. Genet. 21:385-389.
17. Kutlin, A., C. Flegg, D. Stenzel, T. Reznik, P. M. Roblin, S. Mathews, P. Timms, and M. R. Hammerschlag. 2001. Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model. J. Clin. Microbiol. 39:3721-3723.
18. Kutlin, A., P. M. Roblin, and M. R. Hammerschlag. 1999. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob. Agents Chemother. 43:2268-2272.
19. Kutlin, A., P. M. Roblin, and M. R. Hammerschlag. 2002. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model. Antimicrob. Agents Chemother. 46:409-412.
20. Lenart, J., A. A. Andersen, and D. D. Rockey. 2001. Growth and development of tetracycline-resistant Chlamydia suis. Antimicrob. Agents Chemother. 45:2198-2203.
21. Misyurina, O. Y., E. V. Chipitsyna, Y. P. Finashutina, V. N. Lazarev, T. A. Akopian, A. M. Savicheva, and V. M. Govorun. 2004. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob. Agents Chemother. 48:1347-1349.
22. Morrissey, I., H. Salman, S. Bakker, D. Farrell, C. M. Bebear, and G. Ridgway. 2002. Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J. Antimicrob. Chemother. 49:757-761.
23. Musher, D. M., M. E. Dowell, V. D. Shortridge, R. K. Flamm, J. H. Jorgensen, P. Le Magueres, and K. L. Krause. 2002. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:630-631.
24. Nash, K. A., and C. B. Inderlied. 1995. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents Chemother. 39:2625-2630.
25. Nash, K. A., and C. B. Inderlied. 1996. Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. Antimicrob. Agents Chemother. 40:1748-1750.
26. Pankuch, G. A., S. A. Jueneman, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 1998. In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2914-2918.
27. Putman, M., H. van Veen, and W. Konings. 2000. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64:672-693.
28. Read, T. D., R. C. Brunham, C. Shen, S. R. Gill, J. F. Heidelberg, O. White, E. K. Hickey, J. Peterson, T. Utterback, K. Berry, S. Bass, K. Linher, J. Weidman, H. Khouri, B. Craven, C. Bowman, R. Dodson, M. Gwinn, W. Nelson, R. DeBoy, J. Kolonay, G. McClarty, S. L. Salzberg, J. Eisen, and C. M. Fraser. 2000. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res. 28:1397-1406.
29. Roberts, M. C., J. Sutcliffe, P. Courvalin, L. B. Jensen, J. Rood, and H. Seppala. 1999. Nomenclature for macrolide and macrolide-lincosamide- streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43:2823-2830.
30. Roblin, P. M., and M. R. Hammerschlag. 1998. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob. Agents Chemother. 42:194-196.
31. Roblin, P. M., G. Montalban, and M. R. Hammerschlag. 1994. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob. Agents Chemother. 38:1588-1589.
32. Saltzman, L., and D. Apirion. 1976. Binding of erythromycin to the 50S ribosomal subunit is affected by alterations in the 30S ribosomal subunit. Mol. Gen. Genet. 143:301-306.
33. Somani, J., V. B. Bhullar, K. A. Workowski, C. E. Farshy, and C. M. Black. 2000. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. 181:1421-1427.
34. Suchland, R. J., W. M. Geisler, and W. E. Stamm. 2003. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob. Agents Chemother. 47:636-642.
35. Suvorov, A. N., B. van Gemen, and P. H. van Knippenberg. 1988. Increased kasugamycin sensitivity in Escherichia coli caused by the presence of an inducible erythromycin resistance (erm) gene of Streptococcus pyogenes. Mol. Gen. Genet. 215:152-155.
36. Tait-Kamradt, A., T. Davies, P. C. Appelbaum, F. Depardieu, P. Courvalin, J. Petitpas, L. Wondrack, A. Walker, M. R. Jacobs, and J. Sutcliffe. 2000. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob. Agents Chemother. 44:3395-3401.
37. Tait-Kamradt, A., T. Davies, M. Cronan, M. R. Jacobs, P. C. Appelbaum, and J. Sutcliffe. 2000. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. 44:2118-2125.
38. Vester, B., and S. Douthwaite. 2001. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob. Agents Chemother. 45:1-12.
39. Wjrick, P. B., S. T. Knight, T. R. Paul, R. G. Rank, and C. S. Barbier. 1999. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis. J. Infect. Dis. 179:954-966.